

**UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF VIRGINIA  
Richmond Division**

FEDERAL TRADE COMMISSION,	)	
	)	
Petitioner,	)	
v.	)	Misc. No. 3:14-mc-005-REP
	)	
RECKITT BENCKISER	)	
PHARMACEUTICALS, INC.,	)	
	)	
Respondent	)	
	)	

**DECLARATION OF NANCY SCHROM  
IN SUPPORT OF RESPONDENT'S MOTION TO TRANSFER**

I, Nancy Schrom, hereby declare and state as follows:

1. I am the North American Regional Counsel of Reckitt Benckiser Pharmaceuticals, Inc., and I submit this declaration in support of Reckitt's Motion to Transfer the above-captioned action from the Eastern District of Virginia to the Eastern District of Pennsylvania. Unless otherwise indicated below, the statements in this declaration are based upon my personal knowledge or corporate records maintained by Reckitt in the ordinary course of business. I am of legal age and otherwise competent to make this statement.

2. Reckitt is a Delaware company with its principal place of business in Virginia. Reckitt is an indirect, wholly-owned subsidiary of Reckitt Benckiser Group, plc, a British corporation.

3. Reckitt began selling Suboxone in the United States in 2002, and has transacted this business throughout the nation, including making Suboxone sales in the Eastern District of Pennsylvania.

4. Reckitt, along with Reckitt Benckiser Group plc and two other subsidiaries (Reckitt Benckiser LLC, formerly Reckitt Benckiser, Inc.; and Reckitt Benckiser Healthcare (UK) Ltd.) were named as defendants in multiple class-action lawsuits filed beginning in December 2012 arising out of Reckitt's conduct with respect to Suboxone. Unlike Reckitt, the other US-based subsidiary has its principal place of business in New Jersey. Along with this subsidiary Reckitt maintains certain of its files and IT systems in New Jersey.

5. Several generic drug companies have submitted Abbreviated New Drug Applications referencing Suboxone. These companies include both Amneal Pharmaceuticals, LLC, and Actavis Elizabeth LLC, both of which are headquartered in New Jersey. Reckitt negotiated with these companies concerning the potential use of a Single Shared REMS program, including two in-person meetings in the District of Columbia.

6. In connection with its Suboxone activities – including Suboxone marketing, the Single Shared REMS negotiations, and Citizen's Petition that Reckitt submitted to the FDA in 2012 – Reckitt engaged outside counsel from Hyman, Phelps, & McNamara PC to provide legal advice. These counsel included David Clissold, Roger Thies, Josephine Torrente, and Delia Stubbs. These lawyers, and their firm, are located in the District of Columbia.


7. The 2012 Citizen's Petition was based on data obtained from the Researched Abuse, Diversion, and Addiction-Related Surveillance System, an independent, non-profit organization of the Rocky Mountain Poison and Drug Center, a division of Denver Health and Hospital Authority, which is incorporated, and maintains its principal place of business, in Colorado. Also in connection with the same Citizen's Petition, Reckitt engaged Batisha Anson, of BioSector 2's New York office, to provide public relations advice.

8. Reckitt has also been represented by other outside counsel in connection with its Suboxone business. Daniel Ladow, of Troutman Sanders's New York office, provides legal advice with respect to enforcing Reckitt's intellectual property rights. Brian Malkin, formerly of Frommer, Lawrence & Haug's New York and District of Columbia offices, provided legal advice with respect to other FDA citizen's petitions.

9. Suboxone Film is made using patented technology licensed from MonoSol Rx, a Delaware company with its principal place of business in New Jersey.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on this 3rd day of September, 2014.

  
Nancy Schron

**CERTIFICATE OF SERVICE**

I hereby certify that on this 3rd day of September, 2014, I electronically filed the foregoing with the Clerk of the Court using the CM/ECF System which will then send a notification of such filing (NEF) to the following:

Burke W. Kappler  
FEDERAL TRADE COMMISSION  
600 Pennsylvania Ave. NW  
Washington, DC 20580  
T: (202) 326-2043  
bkappler@ftc.gov

Robert P. McIntosh  
UNITED STATES ATTORNEY'S OFFICE  
600 E. Main St., 18th Floor  
Richmond, VA 23219  
T: (804) 819-5400  
Robert.Mcintosh@usdoj.gov

*Counsel for Petitioner*

*/s/ William V. O'Reilly*  
William V. O'Reilly (VSB No. 26249)  
Mark R. Lentz (VSB No. 77755)  
JONES DAY  
51 Louisiana Avenue, NW  
Washington, DC 20001  
Tel: 202.879.3939  
Fax: 202.626.1700  
woreilly@jonesday.scom  
mrlentz@jonesday.com

*Counsel for Respondent*